日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies

非扎单抗对肾移植活检中抗体介导排斥反应分子表型的影响

Diebold, Matthias; Gauthier, Patrick T; Mayer, Katharina A; Mackova, Martina; Hinze, Christian; Chang, Jessica; Patel, Uptal D; Schütz, Ekkehard; Jilma, Bernd; Schrezenmeier, Eva; Budde, Klemens; Böhmig, Georg A; Halloran, Philip F

Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine

以肾脏为中心的无偏分子分型方法对慢性肾脏病进行分类,是迈向精准医疗的重要一步。

Reznichenko, Anna; Nair, Viji; Eddy, Sean; Fermin, Damian; Tomilo, Mark; Slidel, Timothy; Ju, Wenjun; Henry, Ian; Badal, Shawn S; Wesley, Johnna D; Liles, John T; Moosmang, Sven; Williams, Julie M; Quinn, Carol Moreno; Bitzer, Markus; Hodgin, Jeffrey B; Barisoni, Laura; Karihaloo, Anil; Breyer, Matthew D; Duffin, Kevin L; Patel, Uptal D; Magnone, Maria Chiara; Bhat, Ratan; Kretzler, Matthias

Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial

Selonsertib治疗糖尿病肾病患者:一项2b期随机活性导入临床试验

Heerspink, Hiddo J L; Perkovic, Vlado; Tuttle, Katherine R; Pergola, Pablo E; Mahaffey, Kenneth W; Patel, Uptal D; Ishida, Julie H; Kuo, Albert; Chen, Fang; Kustra, Robert; Petrovic, Vladimir; Rossing, Peter; Kashihara, Naoki; Chertow, Glenn M

Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy

一项评估 Felzartamab 治疗抗磷脂酶 A2 受体自身抗体阳性原发性膜性肾病安全性和有效性的 1b/2a 期研究

Rovin, Brad H; Ronco, Pierre M; Wetzels, Jack F M; Adler, Sharon G; Ayoub, Isabelle; Zaoui, Philippe; Han, Seung Hyeok; Dudani, Jaideep S; Gilbert, Houston N; Patel, Uptal D; Manser, Paul T; Jauch-Lembach, Julia; Faulhaber, Nicola; Boxhammer, Rainer; Härtle, Stefan; Sprangers, Ben

Clinical Outcomes Among High-Risk Primary Care Patients With Diabetic Kidney Disease: Methodological Challenges and Results From the STOP-DKD Study

高危糖尿病肾病初级保健患者的临床结局:STOP-DKD 研究的方法学挑战和结果

Bosworth, Hayden B; Patel, Uptal D; Lewinski, Allison A; Davenport, Clemontina A; Pendergast, Jane; Oakes, Megan; Crowley, Matthew J; Zullig, Leah L; Patel, Sejal; Moaddeb, Jivan; Miller, Julie; Malone, Shauna; Barnhart, Huiman; Diamantidis, Clarissa J

Call for Greater Adoption of Recommended Standards during Cancer Drug Development to Improve Cancer Care with CKD

呼吁在癌症药物研发过程中更广泛地采用推荐标准,以改善慢性肾病患者的癌症治疗。

Patel, Uptal D

Race, Income, and Medical Care Spending Patterns in High-Risk Primary Care Patients: Results From the STOP-DKD (Simultaneous Risk Factor Control Using Telehealth to Slow Progression of Diabetic Kidney Disease) Study

高危初级保健患者的种族、收入和医疗保健支出模式:来自 STOP-DKD(利用远程医疗同时控制风险因素以延缓糖尿病肾病进展)研究的结果

Machen, Leah; Davenport, Clemontina A; Oakes, Megan; Bosworth, Hayden B; Patel, Uptal D; Diamantidis, Clarissa

Urinary Single-Cell Profiling Captures the Cellular Diversity of the Kidney

尿液单细胞分析揭示肾脏细胞多样性

Abedini, Amin; Zhu, Yuan O; Chatterjee, Shatakshee; Halasz, Gabor; Devalaraja-Narashimha, Kishor; Shrestha, Rojesh; S Balzer, Michael; Park, Jihwan; Zhou, Tong; Ma, Ziyuan; Sullivan, Katie Marie; Hu, Hailong; Sheng, Xin; Liu, Hongbo; Wei, Yi; Boustany-Kari, Carine M; Patel, Uptal; Almaani, Salem; Palmer, Matthew; Townsend, Raymond; Blady, Shira; Hogan, Jonathan; Morton, Lori; Susztak, Katalin

Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy

一项II期、随机、双盲、多中心研究,旨在评估filgotinib和lanraplenib治疗狼疮性膜性肾病患者的安全性和有效性。

Baker, Matthew; Chaichian, Yashaar; Genovese, Mark; Derebail, Vimal; Rao, Panduranga; Chatham, Winn; Bubb, Michael; Lim, Sam; Hajian, Hooman; Gurtovaya, Oksana; Patel, Uptal; Tumlin, James

Effects of Selonsertib in Patients with Diabetic Kidney Disease

Selonsertib 对糖尿病肾病患者的影响

Chertow, Glenn M; Pergola, Pablo E; Chen, Fang; Kirby, Brian J; Sundy, John S; Patel, Uptal D